LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $59,000 | -38.5% | 24,000 | -36.8% | 0.01% | -41.2% |
Q3 2021 | $96,000 | -11.1% | 38,000 | 0.0% | 0.02% | -15.0% |
Q2 2021 | $108,000 | +575.0% | 38,000 | +442.9% | 0.02% | +400.0% |
Q1 2021 | $16,000 | +33.3% | 7,000 | 0.0% | 0.00% | +33.3% |
Q4 2020 | $12,000 | – | 7,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |